Cairn Investment Group Inc. increased its holdings in Pfizer Inc. (NYSE:PFE – Get Rating ) by 4.0% during the first quarter, according to its most recent disclosure with the SEC. The firm owned 22,821 shares of the biopharmaceutical company’s stock after purchasing an additional 870 shares during the period. The holdings of Cairn Investment Group Inc. in Pfizer were worth $1,783,000 at the end of the most recent reporting period.
A number of other hedge funds and other institutional investors have also bought and sold shares of PFE. Central Bank & Trust Co. raised its stake in shares of Pfizer by 17.0% during the fourth quarter. Central Bank & Trust Co. now owns 24,163 shares of the biopharmaceutical company’s stock valued at $1,427,000 after purchasing an additional 3,518 shares during the period. First Midwest Bank Trust Division boosted its stake in shares of Pfizer by 5.6% in the fourth quarter. First Midwest Bank Trust Division now owns 89,409 shares of the biopharmaceutical company’s stock valued at $5,279,000 after buying an additional 4,775 shares during the period. HNP Capital LLC raised its stake in shares of Pfizer by 12.0% in the fourth quarter. HNP Capital LLC now owns 18,221 shares of the biopharmaceutical company’s stock valued at $1,076,000 after buying an additional 1,948 shares during the period. Global Trust Asset Management LLC boosted its stake in shares of Pfizer by 4.9% during the fourth quarter. Global Trust Asset Management LLC now owns 58,988 shares of the biopharmaceutical company’s stock valued at $3,483,000 after purchasing an additional 2,776 shares during the period. Finally, Crescent Capital Consulting LLC raised its stake in shares of Pfizer by 11.9% during the fourth quarter. Crescent Capital Consulting LLC now owns 71,672 shares of the biopharmaceutical company’s stock valued at $4,235,000 after buying an additional 7,627 shares during the period. Hedge funds and other institutional investors own 66.50% of the company’s shares.
Shares of PFE stock opened at $53.17 on Monday. Pfizer Inc. has a 1-year low of $39.46 and a 1-year high of $61.71. The company has a market cap of $298.33 billion, a price-to-earnings ratio of 12.19, a price-to-earnings-growth ratio of 0.64 and a beta of 0.73. The company has a debt-to-equity ratio of 0.43, a quick earnings ratio of 1.13 and a current ratio of 1.39. The firm has a fifty day moving average of $50.98 and a 200 day moving average of $51.79.
Pfizer (NYSE:PFE – Get Rating ) last announced its quarterly earnings results on Tuesday, May 3rd. The biopharmaceutical company reported $1.62 earnings per share (EPS) for the quarter, missing the consensus estimate of $1.66 by ($0.04). Pfizer had a net margin of 26.97% and a return on equity of 38.29%. The firm had revenue of $25.66 billion for the quarter, compared to analyst estimates of $24.73 billion. During the same period last year, the firm reported $0.93 EPS. The business’s revenue was up 76.8% compared to the same quarter last year. Analysts predict that Pfizer Inc. will post 6.63 EPS for the current year.
The company also recently announced a quarterly dividend, which will be paid on Tuesday, September 6th. Stockholders of record on Wednesday, June 29th will be paid a dividend of $0.40 per share. This represents a $1.60 annual dividend and a dividend yield of 3.01%. The ex-dividend date of this dividend is Thursday, July 28th. Pfizer’s dividend payout ratio (DPR) is 36.70%.
In related news, SVP Jennifer B. Damico sold 4,218 shares of Pfizer stock in a transaction dated Tuesday, June 7th. The shares were sold at an average price of $53.96, for a total transaction of $227,603.28. Following the sale, the senior vice president now directly owns 10,846 shares in the company, valued at $585,250.16. The sale was disclosed in a document filed with the SEC, which is available on the SEC’s website. Also, EVP William R. Carapezzi, Jr. sold 32,908 shares of Pfizer stock in a transaction dated Thursday, May 12th. The shares were sold at an average price of $50.00, for a total transaction of $1,645,400.00. Following the sale, the executive vice president now owns 38,146 shares in the company, valued at $1,907,300. Disclosure of this sale can be found here. Over the last three months, insiders have sold 41,126 shares of company stock worth $2,075,003. Corporate insiders own 0.05% of the company’s stock.
A number of analysts recently issued reports on PFE shares. StockNews.com raised shares of Pfizer from a “buy” rating to a “strong-buy” rating in a research note on Tuesday, April 19th. SVB Leerink initiated coverage on shares of Pfizer in a research report on Monday, May 23rd. They set a “market perform” rating and a $55.00 target price for the company. Wells Fargo & Company cut their target price on shares of Pfizer from $60.00 to $55.00 in a research report on Wednesday, May 4th. Berenberg Bank set a $50.00 target price on shares of Pfizer in a research report on Friday, May 27th. Finally, JPMorgan Chase & Co. set a $57.00 target price on shares of Pfizer in a research report on Tuesday, June 28th. Nine equities research analysts have rated the stock with a hold rating, ten have issued a buy rating and one has issued a strong buy rating to the company’s stock. The stock currently has an average rating of “Moderate Buy” and an average target price of $56.95, according to MarketBeat.
Pfizer Company Profile (Get Rating)
Pfizer Inc discovers, develops, manufactures, markets, distributes and sells biopharmaceutical products worldwide. Offers drugs and vaccines in various therapeutic areas, including cardiovascular metabolic and women’s health under the Premarin and Eliquis brands; biologics, small molecules, immunotherapies and biosimilars under the Ibrance, Xtandi, Sutent, Inlyta, Retacrit, Lorbrena and Braftovi brands; and sterile injectable and anti-infective drugs and oral treatments for COVID-19 under the brand names Sulperazon, Medrol, Zavicefta, Zithromax, Vfend, Panzyga and Paxlovid.
Get Pfizer news and ratings daily – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings for Pfizer and related companies with MarketBeat.com’s FREE daily email newsletter.